采用GastroPlus預測PK曲線或PK參數的應用文章 （2011—2020）
導 讀
凡默谷技術部精取了2011-2020年10月采用GastroPlus預測PK曲線或PK參數的應用文章70篇。
其中序號1-17的文章是2019年8月-2020年10月新增文章。
希望對您的業務或專業學習有所幫助。內容如下：
IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A, Pepin X, Aarons L, Wang Y, Darwich AS, Wood JM, et al. Eur J Pharm Biopharm. Volume 156, November 2020, Pages 50-63. IF= 4.604
2. 使用液相色譜-四極桿飛行時間質譜法測定大鼠血漿中的carisbamate，并使用生理藥代動力學PBPK模型預測其人體PK
A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment.
Schiff bases of 4-Phenyl-2-Aminothiazoles as hits to new antischistosomals: Synthesis, in vitro, in vivo and in silico studies.
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades.
In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385.
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats.
Gender effect on the pharmacokinetics of thymoquinone: Preclinical investigation and in silico modeling in male and female rats.
Combination of Gemcitabine with Cell-Penetrating Peptides: A Pharmacokinetic Approach Using In Silico Tools.
Changes in murine respiratory dynamics induced by aerosolized carfentanil inhalation: efficacy of naloxone and naltrexone.
Utilizing the Combination of Binding Kinetics and Micro-Pharmacokinetics Link in Vitro α-Glucosidase Inhibition to in Vivo Target Occupancy.
Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model.
A Randomized, Open‐Label, Crossover Phase 1 Study to Evaluate the Effects of Food on the Pharmacokinetics of a Single Oral Dose of a 15‐mg Tylerdipine Tablet in Healthy Chinese Male Volunteers.
Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling.
Prediction of ticagrelor and its active metabolite in liver cirrhosis populations using a physiologically based pharmacokinetic model involving pharmacodynamics.
Integration of Precipitation Kinetics From an In vitro, Multicompartment Transfer System and Mechanistic Oral Absorption Modeling for Pharmacokinetic Prediction of Weakly Basic Drugs.
Application of a Dynamic Fluid & pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus?.
Hens B, Bolger MB. J Pharm Sci. January 2019 Volume 108, Issue 1, Pages 305–315. IF=3.616
23. 一種新型選擇性ERα共價拮抗劑（SERCA），H3B-6545的非臨床藥代動力學和體外代謝
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
Rioux N, Smith S, Korpal M, O’Shea M, Prajapati S, Warmuth M, Smith PG. Cancer Chemotherapy and Pharmacology. November 2018. pp 1–10. IF=2.967
24. 受溶酶體捕獲的藥物（如右美沙芬），其制劑處方的標準制定與體外溶出不相關
The Irrelevance of in vitro Dissolution in Setting Product Specifications for Drugs like Dextromethorphan that are Subject to Lysosomal Trapping.
Bolger MB, Macwan J, Sarfraz M, Almukainzi M, L?benberg R. J Pharm Sci.Volume 108, Issue 1, January 2019, Pages 268-278. IF=3.616
25. 使用生理藥代動力學PBPK模型評估的結構和藥代動力學性質相似的化合物
Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
Ellison CA. Regul Toxicol Pharmacol. 2018 Sep 8;99:61-77. IF=2.652
26. 基于hPEPT1絕對表達量建立伐昔洛韋的生理藥代動力學PBPK模型及其應用
A physiologically based pharmacokinetic model for valacyclovir established based on absolute expression quantity of hPEPT1 and its application.
Sun L, Wang C, Zhang Y. Eur J Pharm Sci. 2018 Oct 15;123:560-568. IF=3.616
27. 根據堿性鹽形藥物在胃酸過少或胃酸缺乏的生物相關介質中數據，建立其基于生理學的吸收模型
Physiologically Based Absorption Modeling of Salts of Weak Bases Based on Data in Hypochlorhydric and Achlorhydric Biorelevant Media.
Kesisoglou F, Vertzoni M, Reppas C. AAPS PharmSciTech. 2018 Jun 5. IF=2.401
28. 一種新型口服抗癌藥物的藥代動力學和種屬間放大
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug.
SHetA2. Sharma A, Benbrook MD, Woo S. PLoS One. 2018 Apr 10;13(4): e0194046.IF=2.74
29. 肌氨酸在大鼠中的絕對口服生物利用度：揭開神話的面紗
Absolute Oral Bioavailability of Creatine Monohydrate in Rats: Debunking a Myth.
Alraddadi EA, Lillico R, Vennerstrom JL, Lakowski TM, Miller DW. Pharmaceutics.2018 Mar 8;10(1). pii: E31.IF=4.421
30. 在辛伐他汀載藥的自微乳化藥物遞送系統開發中的體外/計算機模擬方法
In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems.
?etkovi? Z, Cviji? S, Vasiljevi? D. Drug Dev Ind Pharm. 2018 May;44(5):849-860.IF=2.365
31. 在先導化合物優化階段中的生理藥代動力學PBPK模型II：通過全局敏感性分析確認影響生物利用度的性質，從而進行基于生物利用度的合理藥物設計
Physiologically-Based Pharmacokinetic Modeling in Lead Optimization II: “Rational Bioavailability Design” by Global Sensitivity Analysis to Identify Properties Affecting Bioavailability.
Daga PR, Bolger MB, Haworth IS, Clark RD, Martin EJ. Pharmaceutics, 2018, 15 (3), pp 831–839. IF=4.421
32. 在先導化合物優化階段中的生理藥代動力學PBPK模型I：評估GastroPlus在預測系列化合物生物利用度的準確性和適應性
Physiologically-Based Pharmacokinetic Modeling in Lead Optimization I: Evaluation and Adaptation of GastroPlus to Predict Bioavailability of Medchem Series.
Daga PR, Bolger MBHaworth IS, Clark RD, Martin EJ. Pharmaceutics, 2018, 15 (3), pp 821–830. IF=4.421
33. Ribociclib的生物利用度不受胃pH變化或食物攝入的影響：通過計算機預測In Silico和臨床試驗進行評估
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Samant TS, Dhuria S, Lu Y, Laisney M, Yang S, Grandeury A,et,al. Clin Pharmacol Ther. 2017 Nov 14.IF=6.565
34. 采用定量藥理學的方法進行藥物誘發的致心律失常的風險評估：生理藥代動力學PBPK模型
Quantitative Systems Pharmacology Approach for Risk Assessment on Drug-Induced Proarrhythmic Effects with Physiologically Based Pharmacokinetic Model.
Nakamura M, Yoneyama F, Hirata A, Fujishima K, Saito R. J Pharmacol Toxicol.Volume 88, Part 2, November–December 2017, Page 183.IF=2.252
35. 用靜態和PBPK模型預測氯沙坦給藥后,氯沙坦-活性的羧酸代謝物在體內的暴露
Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.
Nguyen H Q, Lin J, Kimoto E, et al. J Pharm Sci. 2017. IF=3.616
36. 開發具有非典型分布行為的藥物的PBPK模型及資質：以地昔帕明為例
Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: A desipramine case study.
Samant T S, Lukacova V, Schmidt S. CPT: Pharmacometrics & Systems Pharmacology, 2017.CiteScore=5.2
37. 針對生物藥劑學數據管理系統中匿名數據的共享和內容管理：首次用于歐盟口服生物藥劑學工具orbito IMI項目
Biopharmaceutics data management system for anonymised data sharing and curation: First application with orbito IMI project.
Lacy-Jones K, Hayward P, Andrews S, et al. Computer Methods and Programs in Biomedicine, 2017, 140: 29-44. IF=3.632
38. 使用生理藥代動力學PBPK模型設計卡維地洛載藥的絲纖蛋白納米粒子的計算機預測In silico-體外-體內研究
In silico-in vitro-in vivo studies of experimentally designed carvedilol loaded silk fibroincasein nanoparticles using physiological based pharmacokinetic model.
Kumar S, Singh S K. International journal of biological macromolecules, 2017, 96: 403-420. IF=5.162
39. 使用生理藥代動力學PBPK模型和生物藥劑學分類BCS交叉預測口服吸收
Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models .
Hansmann S, Darwich A, Margolskee A, et al. Journal of Pharmacy and Pharmacology, 2016, 68(12): 1501-1515. IF=2.571
40. 采用高級房室吸收和轉運ACAT模型預測CYP3A / P-gp對藥物的非線性腸道吸收的相對重要性
The prediction of the relative importance of CYP3A/P-gp to the non-linear intestinal absorption of drugs by advanced compartmental absorption and transit (ACAT) model.
Takano J, Maeda K, Bolger M B, et al. Drug Metabolism and Disposition, 2016: dmd. 116.070011. IF=3.231
41. 用于預測更昔洛韋及其前藥纈更昔洛韋在成人和兒童體內行為的生理藥代動力學PBPK模型
A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children.
Lukacova V, Goelzer P, Reddy M, et al. AAPS J, 2016, 18(6): 1453-1463. IF=3.737
42. 采用臨床微給藥劑量研究探索人Nav1.7電壓依賴性鈉通道的四鐘選擇性抑制劑，在人體內的藥代動力學
Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels.
Jones HM, Butt RP, Webster RW, Gurrell I, Dzygiel P, Flanagan N, Fraier D, Hay T, Iavarone LE, Luckwell J, Pearce H, Phipps A, Segelbacher J, Speed B, Beaumont K. (2016). Clin Pharmacokinet. Feb 19. IF=4.604
43. 開發生理藥代動力學PBPK/藥效學模型，以確定導致恩他卡朋生物利用度低的機理
Alqahtani S, Kaddoumi A. (2015). Biopharm Drug Dispos. Aug 21. IF=1.663
44. 3-deazaneplanocin A（一種潛在的表觀遺傳抗癌劑）的臨床前PK研究，并使用GastroPlus?預測該物質的人體PK
Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?.
Sun F, Lee L, Zhang Z, Wang X, Yu Q, Duan X, Chan E. (2015). Eur J Pharm Sci. Jun 25. IF=3.616
45. 采用生理藥代動力學PBPK模型預測雙環醇控釋制劑在人體的PK
Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.
Wang B, Liu Z, Li D, Yang S, Hu J, Chen H, Sheng L, Li Y. (2015). Eur J Pharm Sci.Jun 24. IF=3.616
46. 基于外推的PBPK模型預測左氧氟沙星在人體中的PK和組織分布
Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.
Zhu L, Zhang Y, Yang J, Wang Y, Zhang J, Zhao Y, Dong W. (2015). Eur J Drug Metab Pharmacokinet. Mar 10. IF=1.913
47. 基于外推PBPK模型預測莫西沙星在腹腔感染人群的體內PK和滲透性
Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model.
Zhu L, Yang J, Zhang Y, Wang Y, Zhang J, Zhao Y, Dong W. (2015). Korean J Physiol Pharmacol. Mar;19(2):99-104. IF=1.805
48. 預測不同制劑的在人和狗中的口服PK：結合生理藥代動力學PBPK模型與具有生物相關性溶出方法
Interspecies prediction of oral pharmacokinetics of different formulations from dogs to human: physiologically based pharmacokinetic modelling combined with biorelevant dissolution.
Wu C, Kou L, Ma P, Gao L, Li B, Li R, Luo C, Shentu J, Hea Z, Sun J. (2015). RSC Adv. 5: 19844. IF=3.119
49. [14C] Cobimetinib（MEK抑制劑）在人體中的吸收，代謝，排泄；及腸道代謝對口服處置的影響
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng A, Rooney I, Gates M, Hop CE, Khojasteh SC, Dresser M, Musib L. (2015). Drug Metab Dispos. Oct. 8.IF=3.231
50. 建立阿托伐他汀的生理藥代動力學PBPK模型
Establishment of physiologically based pharmacokinetic model of atorvastatin.
Liu J-B, Zhu L-Q, Zhang Y, Yang J-W. (2015). Chinese J Hospital Pharmacy.35(16):1465-1469. IF=0.938
51. 新型天然生物堿Jerantinine B的體外抗癌性質和生物學評價
In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B.
Qazzaz ME, Raja VJ, Lim KH, Kam TS, Lee JB, Gershkovich P, Bradshaw TD. (2015).Cancer Lett. Oct 26. IF=7.36
52. 新MDM2拮抗劑（Idasanutlin）在食蟹猴體內的自身誘導作用及該誘導與人體相關性的研究
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Glenn KJ, Yu LJ, Reddy MB, Fretland AJ, Parrott N, Hussain S, Palacios M, Vazvaei F, Zhi J, Tuerck D. (2015). Xenobiotica. Nov 19:1-10. IF=1.902
53. 一種新型的PDE5抑制劑TPN729MA的臨床前PK，并使用PBPK模型預測其人體PK
Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.
Gao ZW Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, Chen XY, Li XN, Zhong DF. (2015).Acta Pharmacol Sin. Dec;36(12):1528-36. IF=5.064
54. 采用生理藥代動力學PBPK模型，指導溶解度具有pH依賴性的化合物的制劑處方和臨床開發
Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility.
Chung J, Alvarez-Nunez F, Chow V, Daurio D, Davis J, Dodds M, Emery M, Litwiler K, Paccaly A, Peng J, Rock B, Wienkers L, Yang C, Yu Z, Wahlstrom J. (2015). J. Pharm. Sci. Jan. 15. IF=3.616
55. 一種用于預防和治療瘧疾的長效二氫乳清酸脫氫酶抑制劑（DSM265）
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, E Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T,et,al. (2015). Sci Transl Med. Jul 15;7(296):296ra111. IF=16.304
56. 21世紀的毒性測試（TT21C）的實施：使用毒性途徑進行安全決策并對原型進行風險評估取得的進展
Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
Adeleye Y, Andersen M, Clewell R, Davies M, Dent M, Edwards S, Fowler P, Malcomber S, Nicol B, Scott A, Scott S, Sun B, Westmoreland C, White A, Zhang Q, Carmichael PL. (2014). Toxicology, Feb 25. IF=4.099
57. 使用生理藥代動力學PBPK模型對YQA-14的臨床前體外和體內ADME性質進行表征并預測在人體內的PK, 這是一種治療藥物成癮的新多巴胺D3受體拮抗劑候選物
Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically-based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
Liu F, Zhuang X, Yang C, Li Z, Xiong S, Zhang Z, Li J, Lu C, Zhang Z. (2014).Biopharm Drug Dispos. Mar 19. IF=1.663
58. 通過基于生理學的吸收模型預測藥物性質對Bitopertin藥代動力學的影響
Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin.
Parrott N, Hainzl D, Scheubel E, Krimmer S, Boetsch C, Guerini E, Martin-Facklam M. (2014). AAPS J. Jun. 27. IF=3.737
59. 對乙酰氨基酚在G?ttingen小型豬中的PK：通過體內研究和建模闡明決定吸收的生理因素
Pharmacokinetics of Pahttp://www.ncbi.nlm.nih.gov/pubmed/24792825racetamol in G?ttingen Minipigs: In Vivo Studies and Modeling to Elucidate Physiological Determinants of Absorption.
Suenderhauf C, Tuffin G, Lorentsen H, Grimm HP, Flament C, Parrott N. (2014).Pharm Res. May 3. IF=3.242
60. 轉化PK / PD模型，并用于評價候選藥物的心血管安全性：藥物開發中的方法和實例
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
Caruso A, Frances N, Meille C, Greiter-Wilke A, Hillebrecht A, Lave T. (2014). J Pharmacol Toxicol Methods. May 28. IF=2.252
61. 對比格犬腸壁和肝臟中CYP450介導的代謝進行體外-體內轉化和基于生理學的建模
In vitro to in vivo extrapolation and physiologically based modeling of cytochrome P450 mediated metabolism in beagle dog gut wall and liver.
Heikkinen AT, Fowler S, Gray L, Li J, Peng Y, Yadava P, Railkar A, Parrott N. (2013).Mol Pharm. Feb. 25. IF=4.321
62. 靶標介導的藥物處置模型在小分子熱休克蛋白90抑制劑中的應用
Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors.
Yamazaki S, Shen Z, Jiang Y, Smith BJ, Vicini P. (2013) Drug Metab Dispos. Apr 4.IF=3.231
63. 采用生理藥代動力學PBPK模型預測Bitopertin的單劑量給藥和多劑量給藥后的人體PK
Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin.
Parrott N, Hainzl D, Alberati D, Hofmann C, Robson R, Boutouyrie B, Martin-Facklam M. (2013). Clin Pharmacokinet. Apr 17. IF=4.604
64. 通過研究HIV-1附著抑制劑磷酸酯前藥的房室吸收模型和吸收部位，來確定開發成緩釋制劑的可行性
Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.
Brown J, Chien C, Timmins P, Dennis A, Doll W, Sandefer E, Page R, Nettles RE, Zhu L, Grasela D. (2013) J Pharm Sci. 102(6):1742-51. IF=3.616
65. 對UK-343,664的非線性吸收進行計算機建模：它是P-gp和CYP3A4的底物
In Silico Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate.
Abuasal BS, Bolger MB, Walker DK, Kaddoumi A. (2012). Mol. Pharm. Feb. 2.IF=4.321
66. 用于預測Patupilone的人體PK的新生理藥代動力學PBPK模型
Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B, Heimbach T, Lin T, He H, Wang Y, Tan E. (2012). Cancer Chemotherapy and Pharmacology. 69(4). IF=2.967
67. 評估磷脂酰肌醇3-激酶/哺乳動物雷帕霉素抑制劑GDC-0980的臨床前吸收和處置，并預測在人體內的PK和藥效
Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human.
Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X. (2012). Drug Metab. Dispos. 40(9):1785-96. IF=3.231
68. 用PBPK模型預測CYP3A底物在人腸道中的代謝-采用GastroPlus?進行評估和應用案例
Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus?.
Heikkinen AT, Baneyx G, Caruso A, Parrott N. (2012). Eur. J. Pharm. Sci. 47(2):375-86. IF=3.616
69. 非甾體孕酮受體拮抗劑PF-02413873的臨床前和臨床PK
Pre-clinical and clinical pharmacokinetics of PF-02413873, a non-steroidal progesterone receptor antagonist.
Bungay PJ, Tweedy S, Howe DC, Gibson KR, Jones HM, Mount NM. (2011). Drug Metab Dispos. May 4. IF=3.231
70. 通過生理藥代動力學PBPK模型理解UK-369,003的臨床藥代動力學
點擊查看其他文獻